PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23328189-1 2013 We tested the hypothesis that olmesartan, an angiotensin II receptor blocker (ARB) devoid of peroxisome proliferator-activated receptor gamma agonist activity, would improve whole-body insulin sensitivity in overweight and obese individuals with elevated blood pressure (BP). olmesartan 30-40 insulin Homo sapiens 185-192 23216584-10 2013 WHAT IS NEW AND CONCLUSION: Olmesartan/amlodipine combination resulted more effective than olmesartan and amlodipine monotherapies in reducing blood pressure, and in increasing insulin sensitivity parameters, but not resulted more effective in improving adipocytokines and interleukins levels analysed, compared with amlodipine or olmesartan monotherapy in hypertensive patients in this double-blind, randomized clinical trial. olmesartan 28-38 insulin Homo sapiens 177-184 23999037-2 2014 The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies. olmesartan 66-76 insulin Homo sapiens 142-149 23815562-2 2013 OBJECTIVES: To evaluate the safety and efficacy of a fixed olmesartan/amlodipine (Olme/Amlo) combination in improving blood pressure control, lipid profile, insulin sensitivity and some inflammatory and insulin resistance markers. olmesartan 59-69 insulin Homo sapiens 157-164 18813860-5 2008 We evaluated whether the ARBs, telmisartan and olmesartan, improved insulin resistance and liver injury by measuring the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and serum alanine aminotransferase (ALT). olmesartan 47-57 insulin Homo sapiens 68-75 22954201-0 2013 Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. olmesartan 0-10 insulin Homo sapiens 102-109 21221601-9 2011 Olmesartan significantly reduced blood pressure and insulin resistance in hypertensive patients with SDB without changing BMI or SDB severity. olmesartan 0-10 insulin Homo sapiens 52-59 21107432-6 2011 Only olmesartan/amlodipine reduced the insulin resistance index (24%, P<0.01), increased plasma adiponectin (16%, P<0.05) and significantly reduced all of the inflammation markers studied, except CRP, which showed a similar reduction in each group. olmesartan 5-15 insulin Homo sapiens 39-46 21061834-8 2010 Patients treated with olmesartan had a significative decrease of total cholesterol, LDL cholesterol, insulin, HOMA and visfatin levels. olmesartan 22-32 insulin Homo sapiens 101-108 21061834-11 2010 CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. olmesartan 34-44 insulin Homo sapiens 70-77 22954201-10 2013 In this randomized, double-blind clinical trial, olmesartan/amlodipine combination resulted more effective than olmesartan and amlodipine monotherapies in reducing BP, in improving insulin resistance, and insulin sensitivity parameters in patients with stage I essential hypertension. olmesartan 49-59 insulin Homo sapiens 181-188 22954201-10 2013 In this randomized, double-blind clinical trial, olmesartan/amlodipine combination resulted more effective than olmesartan and amlodipine monotherapies in reducing BP, in improving insulin resistance, and insulin sensitivity parameters in patients with stage I essential hypertension. olmesartan 49-59 insulin Homo sapiens 205-212 18813860-5 2008 We evaluated whether the ARBs, telmisartan and olmesartan, improved insulin resistance and liver injury by measuring the homeostasis model assessment ratio of insulin resistance (HOMA-IR) and serum alanine aminotransferase (ALT). olmesartan 47-57 insulin Homo sapiens 159-166 18813860-6 2008 The incidence of obesity (BMI > or =25 kg/m2) was significantly higher in Group A than in Groups B and C. The incidence of insulin resistance (HOMA-IR > or =2.5) in Groups A and B was significantly higher than in Group C. Regular doses of telmisartan and olmesartan significantly improved HOMA-IR and ALT levels not only in NAFLD patients but also in patients with CH-C. olmesartan 261-271 insulin Homo sapiens 126-133 18813860-8 2008 In conclusion, telmisartan and olmesartan improved insulin sensitivity and may possibly be used as liver protecting agents in CH-C as well as NAFLD patients. olmesartan 31-41 insulin Homo sapiens 51-58 18310964-0 2008 Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. olmesartan 33-43 insulin Homo sapiens 80-87 18622238-13 2008 In the skeletal muscle, insulin signaling was restored by olmesartan, whereas enalapril was less effective. olmesartan 58-68 insulin Homo sapiens 24-31 18310964-1 2008 OBJECTIVE: To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients. olmesartan 59-69 insulin Homo sapiens 112-119 15127887-2 2004 In this study we addressed this issue by investigating how a newly developed ARB, olmesartan medoxomil, influenced insulin sensitivity and TG metabolism in fructose-fed rats, a representative animal model of insulin resistance. olmesartan 82-92 insulin Homo sapiens 115-122 17130263-10 2006 Olmesartan treatment resulted in a significant decrease of BP, urinary protein excretion, plasma glucose (99 +/- 16 versus 92 +/- 14 mg/dl; P < 0.05), insulin (23.1 +/- 8.8 versus 19.9 +/- 9; P < 0.05), HOMA index (6.0 +/- 2.7 versus 4.7 +/- 2.8; P < 0.05), and glycated hemoglobin (5.33 +/- 0.58 versus 4.85 +/- 0.81%; P < 0.01). olmesartan 0-10 insulin Homo sapiens 154-161 15127887-0 2004 Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. olmesartan 0-10 insulin Homo sapiens 69-76 15127887-5 2004 The area under the curve of insulin (AUCI) was substantially greater in fructose-fed rats in the intravenous glucose tolerance test, and olmesartan treatment significantly reduced the AUCI. olmesartan 137-147 insulin Homo sapiens 28-35 15127887-6 2004 Olmesartan significantly improved the insulin sensitivity index in fructose-fed rats assessed by Bergman"s minimal model without affecting insulin-independent glucose disposal. olmesartan 0-10 insulin Homo sapiens 38-45 15127887-10 2004 Olmesartan ameliorates insulin resistance and overproduction of TG in fructose-fed rats, and these effects appear to be independent of its hypotensive action. olmesartan 0-10 insulin Homo sapiens 23-30